Quercetagetin

Quercetagetin

SCHEMBL29608135

O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)c(O)c(O)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AMY1A P0DUB6 4/20 1.00
PIM1 P11309 3/20 1.00
CD38 P28907 3/20 1.00
MAPK8 P45983 2/20 0.77
MEN1 O00255 9/20 0.72
KMT2A Q03164 9/20 0.72
KDM4E B2RXH2 8/20 0.72
ALOX15 P16050 7/20 0.72
CYP3A4 P08684 7/20 0.72
HSD17B10 Q99714 7/20 0.72
MAPT P10636 7/20 0.72
RECQL P46063 6/20 0.72
CYP2C9 P11712 6/20 0.72
TP53 P04637 5/20 0.72
SLCO2B1 O94956 5/20 0.72
ALDH1A1 P00352 5/20 0.72
HPGD P15428 5/20 0.72
APP P05067 5/20 0.72
XDH P47989 5/20 0.72
CYP1A2 P05177 4/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quercetagetin SCHEMBL29690479 1.00 AMY1A (1.00) AMY1APIM1CD38MAPK8MEN1
Quercetagetin SCHEMBL554527 1.00 AMY1A (1.00) AMY1APIM1CD38MAPK8MEN1
Quercetagetin SCHEMBL7647221 0.94 AMY1A (0.89) AMY1APIM1CD38MAPK8MEN1
Quercetagetin SCHEMBL28164757 0.93 AMY1A (0.87) AMY1APIM1CD38MAPK8MEN1
SCHEMBL31022147 0.90 AMY1A (0.81) AMY1APIM1CD38MAPK8MEN1
SCHEMBL4879748 0.88 AMY1A (0.78) AMY1APIM1CD38MAPK8MEN1
SCHEMBL25926916 0.87 MAPK8 (1.00) AMY1APIM1CD38MAPK8MEN1
SCHEMBL14259668 0.87 AMY1A (0.77) AMY1APIM1CD38MAPK8MEN1
SCHEMBL26255803 0.87 AMY1A (0.77) AMY1APIM1CD38MAPK8MEN1
SCHEMBL12557418 0.87 AMY1A (0.77) AMY1APIM1CD38MAPK8MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250009655-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC 2025-01-09 US claimed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
EP-4181856-A1 PARTICULATES OF POLYPHENOLICS AND DISPERSIONS THEREOF NANOPHASE TECHNOLOGIES CORPORATION (US) 2023-05-24 EP claimed
WO-2023064318-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC (US) 2023-04-20 WO claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
US-20260115112-A1 PARTICULATES OF POLYPHENOLICS AND DISPERSIONS THEREOF SOLESENCE INC (US) 2026-04-30 US disclosed
US-12485075-B2 Particulates of polyphenolics and dispersions thereof Solésence, Inc. (US) 2025-12-02 US disclosed
US-12390418-B2 Biphasic compositions comprising one or both of carbonate and phosphate Natural Extraction Systems, LLC (US) 2025-08-19 US disclosed
CN-119732444-A Composition for improving eggshell quality and application thereof 晨光生物科技集团股份有限公司 2025-04-01 CN disclosed
US-12233073-B2 Skin care formulations and skin cancer treatment REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2025-02-25 US disclosed
US-20250009655-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC 2025-01-09 US disclosed
EP-4181856-A1 PARTICULATES OF POLYPHENOLICS AND DISPERSIONS THEREOF NANOPHASE TECHNOLOGIES CORPORATION (US) 2023-05-24 EP disclosed
CN-116133636-A Particulate matter of polyphenol and dispersion thereof 纳米技术有限公司 2023-05-16 CN disclosed
WO-2023064318-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC (US) 2023-04-20 WO disclosed
CN-110818553-B Anti-inflammatory compound of desmodium parvifolium and preparation method thereof 青海师范大学 2022-06-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115112-A1 PARTICULATES OF POLYPHENOLICS AND DISPERSIONS THEREOF CUTA, HAAO, PPARG AMY1A 1953/4885PIM1 1370/4885CD38 2221/4885
US-12233073-B2 Skin care formulations and skin cancer treatment TP53RK, PRP4K, TP53 AMY1A 4607/4885PIM1 1015/4885CD38 4699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.